WHY IS IT ESSENTIAL TO KEEP THE PAP? BECAUSE THEY’RE WORTH IT

Objectives: Given the recent debate challenging the contribution of cytology in cervical screening, we evaluated results of liquid-based cytology (LBC) and human papillomavirus (HPV) testing in cotesting preceding cervical cancer (CxCa) and precancer diagnoses in a national, heterogeneous population. Methods: We assessed the results of cotesting, performed by Quest Diagnostics, in 13,633,071 women 30 years and older, tested 2010 to 2018. Cotest results preceding CxCa or precancer diagnoses were analyzed and stratified by

[1]  M. Schiffman,et al.  An Introduction to the 2019 ASCCP Risk-Based Management Consensus Guidelines , 2020, Journal of lower genital tract disease.

[2]  Chengquan Zhao,et al.  Enhanced Detection of Cervical Cancer and Precancer Through Use of Imaged Liquid-Based Cytology in Routine Cytology and HPV Cotesting , 2018, American journal of clinical pathology.

[3]  M. Schiffman,et al.  Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening , 2018, Journal of the National Cancer Institute.

[4]  M. Kyrgiou,et al.  Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis , 2018, British Medical Journal.

[5]  E. Flagg,et al.  Assessment of trends in cervical cancer screening rates using healthcare claims data: United States, 2003–2014 , 2018, Preventive medicine reports.

[6]  M. Schiffman,et al.  Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines , 2017, Journal of lower genital tract disease.

[7]  M. Schiffman,et al.  Why does cervical cancer occur in a state-of-the-art screening program? , 2017, Gynecologic oncology.

[8]  P. Sasieni,et al.  Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case–control study , 2016, British Journal of Cancer.

[9]  P. Sasieni,et al.  Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany , 2015, Journal of Clinical Microbiology.

[10]  R. M. Austin,et al.  Comparison of Cervical Cancer Screening Results Among 256,648 Women in Multiple Clinical Practices , 2015, Cancer cytopathology.

[11]  M. Hakama,et al.  Sensitivity, effect and overdiagnosis in screening for cancers with detectable pre‐invasive phase , 2015, International journal of cancer.

[12]  M. Schiffman,et al.  Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. , 2014, Journal of the National Cancer Institute.

[13]  Clare Gilham,et al.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials , 2014, The Lancet.

[14]  M. Hakama,et al.  The HPV test has similar sensitivity but more overdiagnosis than the Pap test—A randomised health services study on cervical cancer screening in Finland , 2013, International journal of cancer.

[15]  M. Schiffman,et al.  Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV-Positive and HPV-Negative High-Grade Pap Results , 2013, Journal of lower genital tract disease.

[16]  M. Schiffman,et al.  Five-Year Risks of CIN 3+ and Cervical Cancer Among WomenWho Test Pap-Negative But Are HPV-Positive , 2013, Journal of lower genital tract disease.

[17]  W. Quint,et al.  Differences in human papillomavirus type distribution in high‐grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe , 2013, International journal of cancer.

[18]  M. Schiffman,et al.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer , 2012 .

[19]  Joakim Dillner,et al.  Screening and cervical cancer cure: population based cohort study , 2012, BMJ : British Medical Journal.

[20]  David C Wilbur,et al.  The Becton Dickinson FocalPoint GS Imaging System: clinical trials demonstrate significantly improved sensitivity for the detection of important cervical lesions. , 2009, American journal of clinical pathology.

[21]  S. Kabawat,et al.  Performance of a fluid-based, thin-layer papanicolaou smear method in the clinical setting of an independent laboratory and an outpatient screening population in New England. , 2009, Archives of pathology & laboratory medicine.

[22]  J. Cuzick,et al.  Screening and adenocarcinoma of the cervix , 2009, International journal of cancer.

[23]  Charlotte Paul,et al.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. , 2008, The Lancet. Oncology.

[24]  Les Irwig,et al.  Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study , 2007, BMJ : British Medical Journal.

[25]  M. Fremont-Smith,et al.  Comparison of the Surepath™ liquid‐based Papanicolaou smear with the conventional Papanicolaou smear in a multisite direct‐to‐vial study , 2004, Cancer.

[26]  M. Schiffman,et al.  Adding a test for human papillomavirus DNA to cervical-cancer screening. , 2003, The New England journal of medicine.

[27]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[28]  J. Cuzick,et al.  Detection of high‐risk HPV types by the hybrid capture 2 test , 2001, Journal of medical virology.

[29]  V. Moreno,et al.  International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas , 1998, International journal of cancer.

[30]  H. Adami,et al.  International incidence rates of invasive cervical cancer after introduction of cytological screening , 1997, Cancer Causes & Control.

[31]  K R Lee,et al.  Comparison of Conventional Papanicolaou Smears and a Fluid‐Based, Thin‐Layer System for Cervical Cancer Screening , 1997, Obstetrics and gynecology.

[32]  Practice Bulletin No. 168: Cervical Cancer Screening and Prevention. , 2016, Obstetrics and gynecology.

[33]  Hagerstoten.  American society for colposcopy and cervical pathology. , 1999, Journal of lower genital tract disease.